Live Web Chat: Answering Questions on New Lymphoma Treatments

0

Ann LaCasce, MD, a medical oncologist in the Dana-Farber/Brigham and Women’s Cancer Center Adult Lymphoma Program, answered a variety of questions about Hodgkin and non-Hodgkin lymphoma during a live web chat hosted by Dana-Farber last month.

The chat, which featured questions submitted by patients and live viewers, focused on new treatments for lymphoma. Some of the topics discussed included new drugs Ibrutinib and Brentuximab, use of umbilical cord stem cells, and treatments with genetically engineered T-cells.

“There are some questions we still have, but I think the work around T-cells is a very exciting area in lymphoma, and it’s going to have applications in other cancers as well,” LaCasce said.

View a video of the Dec. 18 web chat below. For more information on lymphoma, visit the Dana-Farber Adult Lymphoma Program website.

    Make An Appointment

    For adults: 877-960-1562

    Quick access: Appointments as soon as the next day for new adult patients

    For children: 888-733-4662

    All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

    Latest Tweets

    Dana-Farber @danafarber
    CRISPR, a powerful new tool for editing the #DNA instruction manual in animals and humans, is proving a boon to… https://t.co/t1d9NLEuyT
    Dana-Farber @danafarber
    5 tips to combat the effects of lung cancer #stigma & ensure your diagnosis does not control your life:… https://t.co/IDUagG2qLy
    Dana-Farber @danafarber
    Case Study: Dr. Caron Jacobson profiles how CAR T-cell therapy, recently approved by the @US_FDA for relapsed or re… https://t.co/DWOaVDDAxv

    Republish our posts on your blog

    Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.